ProCervix: Phase I started

Genticel began an open-label, U.S. Phase I trial to evaluate 2 intradermal vaccinations of 600 ug GTL001 given 6 weeks apart in 20 patients ages 25-65 infected with HPV types 16 and/or 18. Patients re...